Patents by Inventor Tianjun Zhou

Tianjun Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heteroaryl compounds for kinase inhibition
    Patent number: 11958850
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: April 16, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela V. West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
  • Heteroaryl Compounds For Kinase Inhibition
    Publication number: 20230102829
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Application
    Filed: August 31, 2021
    Publication date: March 30, 2023
    Inventors: WEI-SHENG HUANG, YONGJIN GONG, FENG LI, NICHOLAS E. BENCIVENGA, DAVID C. DALGARNO, ANNA KOHLMANN, WILLIAM C. SHAKESPEARE, RANNY M. THOMAS, XIAOTIAN ZHU, ANGELA V. WEST, WILLMEN YOUNGSAYE, YUN ZHANG, TIANJUN ZHOU
  • HETEROARYL COMPOUNDS FOR KINASE INHIBITION
    Publication number: 20210323976
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFRand mutant HER2 activity, are described herein.
    Type: Application
    Filed: May 12, 2016
    Publication date: October 21, 2021
    Inventors: Wei-Sheng Huang, Tianjun Zhou, Willmen W. Youngsaye, William C. Shakespeare, Alexey V. Ishchenko, David C. Dalgarno
  • HETEROARYL COMPOUNDS FOR KINASE INHIBITION
    Publication number: 20190218212
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Application
    Filed: January 25, 2019
    Publication date: July 18, 2019
    Inventors: Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela V. West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
  • Heteroaryl compounds for kinase inhibition
    Patent number: 10227342
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: March 12, 2019
    Assignee: ARIAD PHARMACEUTICALS, INC.
    Inventors: Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
  • Choline kinase inhibitors
    Patent number: 9834521
    Abstract: This invention relates to compounds of the general formula (I): in which the variable groups are as identified herein, and to preparation and use of the compounds.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: December 5, 2017
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Stephan G. Zech, Anna Kohlmann, Feng Li, Yihan Wang, Tianjun Zhou, David C. Dalgarno, William C. Shakespeare, Xiaotian Zhu
  • Heteroaryl compounds for kinase inhibition
    Patent number: 9796712
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: October 24, 2017
    Assignee: ARIAD Pharmaceuticals, Inc.
    Inventors: Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Dalgarno, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela V. West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
  • HETEROARYL COMPOUNDS FOR KINASE INHIBITION
    Publication number: 20170253594
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 7, 2017
    Inventors: Wei-Sheng Huang, Yongjin Gong, Feng Li, Nicholas E. Bencivenga, David C. Delgamo, Anna Kohlmann, William C. Shakespeare, Ranny M. Thomas, Xiaotian Zhu, Angela V. West, Willmen Youngsaye, Yun Zhang, Tianjun Zhou
  • HETEROARYL COMPOUNDS FOR KINASE INHIBITION
    Publication number: 20170197962
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Application
    Filed: May 13, 2015
    Publication date: July 13, 2017
    Inventors: Wei-Sheng HUANG, Yongjin GONG, Feng LI, Nicholas E. BENCIVENGA, David C. DALGARNO, Anna KOHLMANN, William C. SHAKESPEARE, Ranny M. THOMAS, Xiaotian ZHU, Angela WEST, Willmen YOUNGSAYE, Yun ZHANG, Tianjun ZHOU
  • HETEROARYL COMPOUNDS FOR KINASE INHIBITION
    Publication number: 20170166598
    Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.
    Type: Application
    Filed: May 13, 2015
    Publication date: June 15, 2017
    Inventors: Wei-Sheng HUANG, Feng LI, David C. DALGARNO, Yongjin GONG, Alexey V. ISHCHENKO, Anna KOHLMANN, William C. SHAKESPEARE, Angela V. WEST, Yongjin XU, Willmen YOUNGSAYE, Yun ZHANG, Tianjun ZHOU, Xiaotian ZHU
  • Novel Choline Kinase Inhibitors
    Publication number: 20160024024
    Abstract: This invention relates to compounds of the general formula (I): in which the variable groups are as identified herein, and to preparation and use of the compounds.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 28, 2016
    Inventors: Stephan G. Zech, Anna Kohlmann, Feng Li, Yihan Wang, Tianjun Zhou, David C. Dalgarno, William C. Shakespeare, Xiaotian Zhu